We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

October 7, 2018

3 Takeaways from the HealthXL Menlo Park Global Gathering

Events
Chandana Fitzgerald
&
As California geared up for Fleet Week, we brought the health parade to the very plush ‘Hangar’ at GE Ventures in Menlo Park on Oct 4th. There’s a jet engine in the Boardroom - this Hangar means business. HXLGG California was a coming together of the ever expanding HealthXL community to discuss healthcare, technology and everything in between. In this week’s blog, we give you the lowdown on the who, what, where and how.

#1 Medication Assisted Treatment (MAT) deserves greater adoption and destigmatization

Lipi Roy, Clinical Assistant Professor NYU Langone Health, made a case for FDA approved, evidence-based medications such as methadone, bupenorphine and naltrexone that have been around for the longest time. They aid in bringing users out of opioid use disorder by binding to the same receptors (except naltrexone, which is an antagonist) as other opioids without the associated euphoric effects. It is not as crass as ‘giving drugs to drug users’. Molly Coye, who is on the Board of Aetna, highlighted how long this has been around for, and yet, we see low adoption among clinicians. A number of doctors don’t know how to prescribe MAT and best practices in management of OUD. Dissemination of information and education to all stakeholders is the missing piece. Yuri Maricich, CMO of the prescription digital therapeutic, Pear Therapeutics, showed us how technology can go hand-in-hand with medication in aiding the recovery from opioid addiction. Their solution, reset-O, works by offering CBT (cognitive behavioural therapy) to assist in the psychological recovery of the patient. Dan Knecht, Head of Clinical Strategy at Aetna outlined some of the ways in which health plans can make MAT and treatments for OUD accessible and widely available to patients. Aetna is seeing progress on its opioid strategy to prevent misuse and abuse, intervene in risky behavior and support members with access to evidence-based treatments. We realize it isn’t enough to bring a group of physician advocates without understanding the needs of the end users - someone who has been through this journey. Jessica Moss, who used to be an opioid user and now proudly sober, challenged our panel about the use of medication to revive people in addiction - as someone who used to be capable of abusing methadone or bupenorphine, she gave us food for thought about some of the challenges in prescribing MAT. All in all, a stimulating and educational conversation for our gathered attendees.



#2 Technology for the sake of technology won’t enable adults with dementia

There are many shiny products out there to support seniors living with dementia. However, a number of them suffer from not being user-centric, and not putting the needs of the patient first. Also read as  ‘what do we think will be useful to you and help us grow a business’. Dissuading that notion are GrandPad who have built a dementia-friendly tablet (yep, hardware + software - no tiny charging points or buttons, no small text) that adults with dementia are happily using all over the USA. GrandPad helps seniors connect with their loved ones. Kerry Burnight moved from academia to the private sector to bring GrandPad to life and place it into the hands of older adults. Rajiv Mehta, CEO of Atlas of Caregiving emphasized on the role of the caregiver in the life of an adult with dementia, and asked to shift the focus from health professionals. He emphasized the importance of tools for measurement and data analysis. Tools meant primarily for those workers. Only they, not distant experts, have the tacit knowledge for interpretation and action. Tech or no tech, there is no care without the caregiver. This coming from an ex-techie, you better believe it! Sean Hogan, GM of IBM Watson Healthcare & Lifesciences, who is personally and professional interested in this area, challenged the panelists on whether we were even addressing the right challenges by laying a focus on technology to enable people with dementia. At the end of the day, we were in the epicenter of Silicon Valley and our audience included pharma, med device and investors, so it wouldn’t be lost to explore the opportunity for them in dementia care. Jennifer Liao heads BD at Evidation Health, the Silicon Valley start-up that is doing some cool data analytics work in health. From having worked with a number of adults with dementia on studies they analysed, she found them to not only be very receptive to using technology, but also spent the time and effort to learn the correct ways to do so. That is promising. Richard Caro heads up The Longevity Explorers community that includes circles of older adults who meet regularly face-to-face, as well as a larger “virtual” community of explorers who participate via the Tech-enhanced Life website and email. Lisa Weitzman is a care worker at the Benjamin Rose Aging Institute and gave a voice to the patient, much like Jessica on the previous session. Lisa spoke of the realities on the ground that she sees everyday, and how we cannot forget that this is a human problem that needs humane approaches. Social isolation is the root cause of worsening severity of cognitive decline, and that, is a problem we can and should do something about. Our panelists sure did have their mike drop moments.



#3 Digital Therapeutics are on the brink of unleashing their potential

Digital health evangelists Lisa Suennen of Venture Valkyrie fame and Bob Kocher, Partner at Venrock Healthcare had a fun chat to explore everything DTx (digital therapeutics). From defining it to understanding if they are ready to work as standalone treatments, from questioning the ridiculous amounts of money being pumped into the industry to whether consumers are ready for DTx (or we are still waiting for physicians to bless the products) - no stone was left unturned. Bob recognized Florida Blue as an organization worth emulating for their initiatives in health innovation. They also delved into the prescription and reimbursement landscapes, value based care, pharma- DTx partnerships. Lisa being Lisa challenged every assumption, and Bob being Bob gave us confidence in the opportunity they hold. As an investor in the space, and a seasoned physician, Bob can see that once DTx crack the regulatory and reimbursement codes, they can truly help populations just the way that drugs can, but better- with more data and connectivity. We may be only 2-3 years away from DTx being an integral part of our health and sickness.

The afternoon’s discussions broke down barriers and encouraged the group to continue sharing thoughts and ideas during the evening reception hosted by the team at GE Ventures. We are not going to move the needle with one afternoon of discussions, but we sure do hope that we have stimulated, challenged, educated and made an impact on the leaders and influencers who gathered. We hope it was a call to action.

Read the event report below to see presentations, attendees and more!

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx-Generated RWD: What is the Value for Pharma?

27th June @ 10:45AM EDT

Real-world data (RWD) can be highly valuable to pharma companies; with several use cases from drug discovery and development to drug market access, label extensions, and understanding how their drugs and competitors are used in real life. Join this meeting to discuss this topic further with others working in this space.

Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate
Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx in the US

30th June @ 10:45AM EDT
Cracking the US market is no mean feat for digital health companies.
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Reimbursement of Digital Health in Europe - the DiGA framework

7th July @ 10AM EDT/ 5PM AWST

Regulatory clearance and the best commercialization model for a digital health product are among the key components for success in a rapidly growing sector. Join this Masterclass led by Flying Health to dive deeper into this topic.

Featuring
Laura Nelde
Laura Nelde
Startup Relationship Manager at Flying Health
Featuring
Laura Nelde
Laura Nelde
Startup Relationship Manager at Flying Health
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

What Label Claims can you make about your DTx?

14th July @ 10:45AM EDT

As the Digital Therapeutics (DTx) industry matures, regulation is becoming increasingly important. Join this meeting to share your experiences with others working in this space.

Featuring
Anish Shindore
Anish Shindore
Founder & Managing Partner, GSD Health
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate
Featuring
Anish Shindore
Anish Shindore
Founder & Managing Partner, GSD Health
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

DTx-Generated RWD: What is the Value for Pharma?

27th June @ 10:45AM EDT

Real-world data (RWD) can be highly valuable to pharma companies; with several use cases from drug discovery and development to drug market access, label extensions, and understanding how their drugs and competitors are used in real life. Join this meeting to discuss this topic further with others working in this space.

Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate
Featuring
Myles Furnace
Myles Furnace
Commercial VP, Closed Loop Medicine
Brian Mahony
Brian Mahony
Medical Device & Digital Medicine Researcher, BioInnovate
Digital Health in Oncology
Digital Health in Oncology
Digital Health in Oncology
Digital Health in Oncology

Innovation Showcase: Digital Patient Support Programs (PSPs) in Oncology

28th June @ 10:45AM EDT

Are you a Digital Health company, Pharma executive, Medtech executive, or Venture Capitalist (VC), working in Patient Support Programs (PSPs) in oncology and seeking guidance to build successful partnerships? Then keep reading, this meeting is for you

Featuring
Fiona Clemente
Fiona Clemente
Digital Health Scouting Officer, WeHealth
Jim Ternyila
Jim Ternyila
Senior Digital Health Commercialization Strategy Leader, The Janssen Pharmaceutical Companies of Johnson & Johnson
Featuring
Fiona Clemente
Fiona Clemente
Digital Health Scouting Officer, WeHealth
Jim Ternyila
Jim Ternyila
Senior Digital Health Commercialization Strategy Leader, The Janssen Pharmaceutical Companies of Johnson & Johnson
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery
Telemedicine & Virtual Care Delivery

What’s in Remote Patient Monitoring Programs for Pharma?

29th June @ 10:45AM EDT

As the Covid-19 pandemic shifted how people interact with healthcare, the relationship between pharma and patients changed as many moved away from conventional clinical settings. Join this meeting to discuss this topic further and share your thoughts and experiences with your peers.

Featuring
Brian Flatley
Brian Flatley
VP Consulting Services at S3 Connected Health
Chris Wasden
Chris Wasden
Head of HappifyDTx, Happify Health
Featuring
Brian Flatley
Brian Flatley
VP Consulting Services at S3 Connected Health
Chris Wasden
Chris Wasden
Head of HappifyDTx, Happify Health
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Sustainable Business Models for DTx in the US

30th June @ 10:45AM EDT
Cracking the US market is no mean feat for digital health companies.
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche
Featuring
Rick Bartels
Rick Bartels
Managing Partner , DTxCC
Ary Deleray
Ary Deleray
Personalized & Digital Health Strategy at Roche

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.